Analysts expect Niagen Bioscience to report Q2 2026 revenue of approximately $32.00 million and earnings per share of $0.01, while the stock currently trades at $3.32, significantly below the $11.83 average analyst price target.
Investors are primarily focused on the growth trajectory of Tru Niagen product sales, especially within the e-commerce segment, as the company faces intensifying competition from B2B manufacturers of NMN.
This quarter represents the first full reporting period following the launch of the "Niagen Plus" telehealth platform, a strategic initiative designed to drive higher-margin direct-to-patient revenue. While management previously reaffirmed a full-year 2026 revenue growth guidance of 10-15%, significant investments in sales and marketing to support new product rollouts are expected to weigh on near-term profitability.